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Abstrak
Latar belakang: Sebagai komponen penting untuk mendukung pelaksanaan program KIA, obat untuk program 
pelayanan obstreti, neonatal emergensi dasar (PONED) harus tersedia di instalasi farmasi kabupaten/kota 
(IFK) di seluruh regional di Indonesia. Namum kadang-kadang terjadi disparitas ketersediaannya. Oleh 
karena itu perlu dilakukan penelitian untuk mengidentifi kasi disparitas Ketersediaan tersebut. 
Metode: Penelitian potong lintang yang merupakan bagian dari Rifaskes 2011 pada bulan Agustus-Oktober 
2011 yang mencakup seluruh 497 IFK kabupaten/kota di 33 provinsi Indonesia. Regional terdiri dari Sumatera, 
Jawa-Bali, Nusa Tenggara, Kalimantan, Sulawesi, Maluku, dan Papua. Obat esensial PONED dibagi menjadi 
dua klasifi kasi: (1) sangat penting, dan (2) penting.
Hasil: Pada Januari 2012, dari 497 kabupaten/kota tersedia 316 (64%) untuk analisis ini. Terdapat disparitas 
obat untuk PONED baik yang tergolong sangat penting maupun yang penting. Di antara obat PONED esensial 
yang sangat penting, Dextrose infus dan Ergomterin/methiler-gometrin injeksi maleat, dan Oxytosin injeksi 
tersedia di semua wilayah kecuali di Maluku. Anti tetanus serum (ATS), Furosemid injeksi, Furosemid injeksi, 
Magnesium sulfat, dan Penicilin prokain tersedia di semua regional. Obat PONED esensial yang penting, kecuali 
obat Bicarbonas di Papua, semua obat esensial PONED kurang tersedia di semua regional. Yang paling tidak 
tersedia adalah infus A2, injeksi Cedilanide, Natrium bikarbonat injeksi, dan petidin injeksi. Secara keseluruhan 
di Nusa Tenggara mempunyai persediaan obat PONED yang relatif lebih baik dibandingkan region lainnya.
Kesimpulan: Terdapat kesenjangan ketersediaan obat esensial PONED yang sangat penting maupun yang 
penting di seluruh di Indonesia. Maka kesenjangan obat-obat PONED ini harus diatasi. (Health Science 
Indones 2012;2:xx-xx)
Kata kunci: ketersediaan obat PONED, disparitas, instalasi farmasi, Indonesia 
Abstract
Background: As an important component to support the implementation of the Basic Emergency Obstetric 
and Neonatal Care (BEONC) the drugs should be available in the district/city pharmacy (IFK) in entire region 
in Indonesia. However, availability disparity occurred. Therefore, it is necessary to describe the disparity on 
the availability drugs in Indonesia.
Methods: A cross-sectional study was conducted in August-October 2011, which covered all IFK districts / 
municipalities in 33 provinces of Indonesia. The location comprised regional: Sumatra, Java and Bali, Nusa 
Tenggara, Kalimantan, Sulawesi, Maluku, and Papua. BEONC essential medicines were divided into two 
classifi cations: (1) very very important, and (2) very important.
Results: In January 2012, out of 497 districts / cities 316 (64%) were available for this analysis. There were disparities 
on availability BEONC classifi ed as very very important as well as very important drugs. Among the very important 
BEONC essential drugs, Dextrose infusion and Ergomterin / methiler-gometrin maleate injection, and injection 
Oxytosin available in all regions except in the Maluku. Anti-tetanus serum (ATS), furosemide injection, furosemide 
injection, Magnesium sulfate, and Procaine Penicillin were available in all regions. The important BEONC essential 
drugs, except Bicarbonas in Papua, all essential drugs BEONC less available in all regions. The most available was 
A2 infusion fl uid, Cedilanide injection, sodium bicarbonate injection, and pethidine injection. It seemed that Nusa 
Tenggara region had relatively better BEONC drug stock as compared to other regions.
Conclusion: There was signifi cantly disparity on availability of very important essential BEONC drugs in all 
regions in Indonesia. Therefore it is necessary to solve the disparity problems of BEONC drugs. (Health Science 
Indones 2012;2:xx-xx) 
Key words: BEONC drug, availability, disparity, pharmaceutical installation, Indonesia 
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The National Health Facility Research (Rifaskes) 2011 
has been conducted by the National Institute of Health 
Research and Development (NIHRD). Rifaskes 2011 
covered all components of input, process and output 
in the public hospital, health center or Puskesmas and 
independent clinical laboratory in Indonesia. One of the 
pertinent components of input in those three targeted 
health facilities is drug. Based on this reason, Rifaskes 
2011 has also included the District/City Pharmaceutical 
Installation (IFK) as the additional research target.1
Two of the eight focus priorities in Five Year (2009-
2014) Strategic Plan of Health Development in Indonesia 
are fi rst, maternal and child health, and second, drugs and 
food availability and control. These two priorities are 
in conjunction with the Millenium Development Goals 
(MDG) number four and fi ve, which are to reduce two 
third of the infant, neonatal and under fi ve children and 
to reduce the maternal mortality, as well as to increase 
the coverage of delivery by trained health provider from 
in the period of 1990 to 2015.2
Both, the Five Year Strategic Plan of Health Deployment 
and MDG, are in line with the target of National Long 
Term Development Plan (2005-2025) mentioned in 
the Law no. 17/2007. This law states that the targets of 
National Long Term Development Plan in Health Sector 
are among others to reduce the IMR and MMR.3
In order to achieve all of targets mentioned above, 
drugs related to the Maternal and Child Health (MCH) 
programs should be available in the IFK as important 
component to support the implementation of basic 
emergency obstetric and neonatal care (BEONC) or 
Comprehensive Emergency Obstetric and Neonatal 
Care (CEONC). The IFK is a storage installation of 
all drugs utilized for health programs in a district/city 
and it is under coordination of district/city health offi ce. 
The IFK has been created to improve the effectiveness 
and effi ciency of all drugs distribution by the district/
city health offi ce regardless the origin of budget used to 
purchase the drugs. From IFK the drugs are ordered to be 
distributed monthly by the district/city health authority 
mainly to the local hospital and health centers. 
Rifaskes 2011 has collected only availability and adequacy 
of general, BEONC, dental and family planning drugs in 
2010 and 2011.4 
The aim of this study was to identify drug availability 
for PONED programs at the district/city pharmaceutical 
installation in the regions of Indonesia
METHODS
The IFK data have been collected as a part of National 
Health Facility Research or Rifaskes 2011, which was 
a cross sectional study carried out between August 
to October 2011 covering 497 districts/cities in 33 
provinces of Indonesia. There was no sampling system 
in this study, because all of the IFKs in 497 districts/
cities were used. The regionals were Sumatera, Jawa-
Bali, Nusa Tenggara, Kalimantan, Sulawesi, Maluku, 
and Papua regional.
The IFK questionnaire was a separate and independent 
questionnaire from the main questionnaire of Rifaskes 
2011. The main variables collected in IFK questionnaire 
were general identifi cation of IFK, availability and 
adequacy of drugs in 2010 (smallest unit of drugs), 
months of drugs inavailability in 2010, and availability 
of drugs (smallest unit of drugs) in 2011. 
All drug data were classifi ed into 44 essential general 
drugs, 17 essential MCH drugs related to BEONC, 11 
essential dental drugs and substances, as well as 10 
family planning drugs and devices. 
Those drugs were chosen by using the list of drugs to 
be monitored by the Directorate General of Pharmacy 
and Health Equipment, MOH, as well as the list 
of important drug for BEONC, dental and family 
planning mentioned in the guideline of BEONC by the 
Directorate General of Community Health, Ministry of 
Health of Indonesia (MOH).5
MCH drugs were divided into two classifi cation: (1) 
very important essential MCH drugs for BEONC; and 
(2) important essential MCH drugs for BEONC. 
The drugs considered available if no stock out within 
fully 12 months of 2010, and not available if one or 
more months within 12 months of 2010 were no stock.
The IFK questionnaire was submitted by district/city 
Rifaskes 2011 technical coordinator or sent by mail 
to the district/city health offi ce by national technical 
coordinator. The questionnaire was then fulfi lled by 
the head and staff of the local IFK.
The fi nal fi lled in questionnaires was collected by 
district/city Rifaskes 2011 technical coordinator or 
sent through mail by the district/city health offi ce to 
the national technical coordinator.
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In Jakarta, the questionnaires were received by data 
manager at NIHR followed by batching, editing, cleaning, 
and data entry. 
For this article, IFK data were analyzed using Chi 
square tests for availability of BEONC drugs in 2010 
by regional in Indonesia. 
RESULTS
By January 2012, only 316 out of 497 districts/cities or 
64%  were received by data manager at NIHRD. Six 
districts in Jakarta Metropolitan Province did not have 
IFK were excluded from the analysis.
Table 1 shows that disparity in availability of BEONC 
very important essential drugs in general occurred in 
all regions. 
Dextrose infusion and Ergomterin/methiler-gometrin 
maleat injection, and Oxytosin injection were more 
available in all regions except in Maluku region which 
less available on Dextrose infusion 5 and Ergomterin/
methiler-gometrin maleat injection.
Anti tetanus serum, Furosemid injection, Furosemid 
injection, Magnesium sulphate, and Penicilin in general 
less likely available in all regions. However NaCl 
infusion was likely more available in all regions.
In general, Nusa Tenggara region had relatively better 
BEONC drug stock as compared to the others
Table 2 shows that except in Papua on Bicarbonas, all 
BEONC essential drugs more likely not available in 
all regions. The most not or not available were fl uid 
infusion solution A2, Cedilanide injection, Natrium 
bicarbonate injection, and Pethidine injection.
DISCUSSION
This study was an additional study in Rifaskes 2011, 
with only 64% of response rate. Due to limitation of the 
surveyors, some of the questionnaires were delivered 
indirectly through the district/city health offi ces with 
limited times for data validation from the installation 
book record. The variables collected by using this 
questionnaires were very limited and could not answer 
why the drugs were available or not available. However, 
with 64% of response rate, at least this study was able 
to show the picture of general and some specifi c drug 
stock availability at national and regional level.   
Table 1. The availability of very important essential BEONC drugs by region

















% % % % % % %
Dextrose infusion 5 Available 60.4 68.1 87.5 54.8 44.2 35.7 72.7
0.004
Not available 39.6 31.9 12.5 45.2 55.8 64.3 27.3
Ergomterine/methiler-
gometrin maleat injection 
0.200 mg/ml
Available 64.8 79.1 91.7 71.4 55.8 35.7 81.8
0.001
Not available 35.2 20.9   8.3 28.6 44.2 64.3 18.2
Oxytosin inj 10 IU/ml - 1 
ml
Available 65.9 87.9 100.0 73.8 67.4 64.3 54.5
0.000
Not available 34.1 12.1   0.0 26.2 32.6 35.7 45.5
Anti Tetanus Serum 10.000 
IU
Available 27.5 23.1 29.2 16.7 7.0 21.4 27.3
0.177
Not available 72.5 76.9 70.8 83.3 93.0 78.6 72.7
NaCl infusion 0.9 Available 69.2 81.3 95.8 66.7 48.8 42.9 81.8
0.000
Not available 30.8 18.7 4.2 33.3 51.2 57.1 18.2
Furosemid injection IV/IM 
10 mg/ml
Available 17.6 19.8 29.2 38.1 14.0 21.4 45.5
0.039
Not available 82.4 80.2 70.8 61.9 86.0 78.6 54.5
Magnesium sulphat 20  Available 36.3 45.1 83.3 50.0 18.6 14.3 27.3
0.000
Not available 63.7 54.9 16.7 50.0 81.4 85.7 72.7
Magnesium sulphat 40  Available 37.4 58.2 91.7 52.4 23.3 28.6 18.2
0.000
Not available 62.6 41.8 8.3 47.6 76.7 71.4 81.8
PP 50.000 IU Available   4.4   5.5 16.7   7.1   4.7   7.1 27.3
0.060
Not available 95.6 94.5 83.3 92.9 95.3 92.9 72.7
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The low stock of BEONC drugs in the above results 
indicated the inadequate of BEONC implementation 
in Health Center. Sri Handayani showed HC with 
inadequate implementation of BEONC in Kendal District 
was due to lack of inter sectorial communication, lack of 
health manpower quantity and quality, inavailability of 
infrastructure and logistic of BEONC (including drug), 
budget insuffi ciency and no signifi cant differences 
between the distance to the hospital and HC.6 
Study of Rachmawati and Suprapto indicated major 
problems to the implementation of BEONC in three 
districts in East Java Province was related to the local 
coordination and policy to support this program. It was 
also found that continuity of BEONC services including 
the availability of BEONC drugs was depend on the 
commitment of those District Health Offi cers and HC 
providers in prioritizing the BEONC programs. In 
those three Districts, inavailability of BEONC drugs 
was compensated by providing recipe to the patients to 
buy those necessary drugs to the pharmaceutical store, 
which was far away and took times.7 
One of the good examples was MCH program 
reformation in East Nusa Tenggara which was formally 
strengthened by the Governor regulation number 42, 
2009. This program was totally carried out in East 
Nusa Tenggara Province, including to accelerate the 
BEONC implementation. This policy probably had 
also impact in the availability of BEONC drug stock, 
in which in the both Table 1 and 2, the regional of 
Table 2. The availability of essential BEONC drugs in the region 















% % % % % % %
Bicarbonas Available 44.0 33.0 33.3 21.4 16.3 14.3 54.5
0.007Not available 56.0 67.0 66.7 78.6 83.7 85.7 45.5
Fluid infusion solution A2 Available     0.0 2.2    0.0 0.0 2.3 0.0   9.1
0.197
Not available 100.0 97.8 100.0 100.0 97.7 100.0 90.9
Cedilanide injection Available 0.0  0.0   0.0  2.4 0.0    0.0   0.0
0.365
Not available 100.0 100.0 100.0 97.6 100.0 100.0 100.0
Dextran 40  Available 17.6 8.8 37.5 23.8 14.0 14.3 18.2
0.037
Not available 82.4 91.2 62.5 76.2 86.0 85.7 81.8
Natrium bicarbonat 
0.83 mEK/ml injection 
(Meylon)
Available   4.4   6.6 12.5   4.8  2.3 7.1 27.3
0.071
Not available 95.6 93.4 87.5 95.2 97.7 92.9 72.7
Pethidin injection 50 mg/
ml
Available 8.8 13.2 45.8 16.7   7.0    9.1
0.000
Not available 91.2 86.8 54.2 83.3 93.0 100.0 90.9
Tramadol inj 100 mg/2 ml Available 20.9 17.6 20.8 33.3 16.3 7.1 18.2
0.338
Not available 79.1 82.4 79.2 66.7 83.7 92.9 81.8
Nusa Tenggara relatively indicated better BEONC 
drug stock in district/city pharmaceutical installation 
as compared to the others.8   
In the preliminary discussion and further discussion 
with the Minister of Health and staff, it was agreed 
about the disparity of drug stock availability in district/
city pharmaceutical installation, especially for BEONC 
drugs. However, some argumentations were raised such 
as the BEONC drugs were mostly distributed directly 
to the BEONC HC and not necessarily to be pooled 
it through the district/city pharmaceutical installation. 
Another possibility was all of BEONC drugs were 
managed by the MCH division at the district/city health 
offi ces and not in those pharmaceutical installations. 
Delayed supply of BEONC drugs was another 
argumentation.9 The results of Rifaskes 2011 for Health 
Center showed signifi cant disparity, insuffi ciency 
and inadequacy of some essential and very essential 
BEONC drugs.10 It seemed the above Rifaskes 2011 
fi ndings rejected all of the argumentations raised in the 
MOH discussion.
In conclusion, the disparity in availability of BEONC 
very important essential drugs in general occurred in 
all regions. In addition, except in Papua on Bicarbonas, 
all BEONC essential drugs more likely not available in 
all regions. The most not or not available were fl uid 
infusion solution A2, Cedilanide injection, Natrium 
bicarbonate injection, and Pethidine injection.  
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